Gapping up
In reaction to strong earnings/guidance: BOX +11.4%, MW +7.6%, KKD +6.2%, DDC +3.4%
M&A news: ISSI +3.6% (Integrated Silicon amends its merger agreement with Uphill Investment, increasing the acquisition price to $21/share from $20/share for ISSI shares), HE +0.6% (shareholders approve merger with NextEra Energy (NEE))
Other news: ATOS +10.7% (announces the U.S. Patent and Trademark Office has issued a new patent, Serial No. 9,052,318, to Atossa for Breast Cancer Detection using Absorbent Paper), ISIS +8% (reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atroph), CLLS +3.4% (announced publication of a study in Molecular Therapy describing the development of the next generation of engineered CAR T-cells compatible with allogeneic adoptive transfer immunotherapy), DMND +2.6% (favorable commentary on Wednesday's Mad Money), RBS +2.1% (UK confirms plans to begin sales of government's RBS stake - will begin in the coming months), AMGN +1.5% (FDA Advisory Committee votes 15-0 in favor of recommending approval of Repatha (evolocumab) for lowering LDL-C in patients with HoFH), AGIO +1.5% (confirms the FDA has granted it orphan drug designation for AG-120 for the treatment of patients with acute myelogenous leukemia), NKE +1.1% (NIKE to become exclusive oncourt provider for NBA, WNBA, NBA D-league), LNG +0.9% (announced 2 significant LNG projects; may add up to 19 mtpa in new liquefaction capacity by 2025), ISBC +0.7% (announced its second share repurchase program; may repurchase an additional 10% of its common stock, or ~34 mln shares)
Analyst comments: PTBI +13.2% (initiated with a Buy at ROTH Capital; tgt $16), AGEN +3.6% (initiated with an Outperform at Oppenheimer), NPTN +2.4% (upgraded to Outperform from Mkt Perform at Raymond James), RAD +2.2% (resumed with a Outperform at Credit Suisse), ERF +2.2% (upgraded to Buy from Hold at TD Securities), HZNP +1.9% (initiated with a Overweight at Morgan Stanley), TOL +1.7% (upgraded to Outperform from Neutral at Credit Suisse), FDX +1.2% (added to Focus List at Citigroup; target raised to $206 from $198 at Credit Suisse ), AWAY +0.8% (initiated with an Overweight at a boutique firm), HOS +0.7% (initiated with an Overweight at Barclays), NFLX +0.7% (target raised to $746 at Topeka Capital Markets), HLT +0.7% (initiated with a Buy at Brean Capital)
